0 638

Cited 6 times in

Serotonin Syndrome Following Combined Administration of Dopaminergic and Noradrenergic Agents in a Patient With Akinetic Mutism After Frontal Intracerebral Hemorrhage: A Case Report

DC Field Value Language
dc.contributor.author김나영-
dc.contributor.author김용욱-
dc.contributor.author박중현-
dc.contributor.author전대근-
dc.date.accessioned2018-07-20T07:46:56Z-
dc.date.available2018-07-20T07:46:56Z-
dc.date.issued2017-
dc.identifier.issn0362-5664-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160513-
dc.description.abstractBACKGROUND: Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergic drugs. CASE PRESENTATION: A 55-year-old man with a right frontal intracerebral hemorrhage extending to the left cerebral hemisphere presented with clinical features of akinetic mutism. Three months after onset, dopaminergic (methylphenidate, levodopa/benserazide) and noradrenergic (atomoxetine) drugs were administered to enhance his cognitive function. His cognitive function gradually improved during 8 weeks of dose escalation. One day after the dose of atomoxetine was increased from 40 mg/d to 60 mg/d, the patient developed inducible clonus, rigidity, diarrhea, tachycardia, and hyperthermia, in keeping with a diagnosis of SS. The symptoms and signs suggestive of SS resolved on the day following cessation of all dopaminergic and noradrenergic drugs. CONCLUSIONS: This case demonstrates that medications generally known as dopaminergic or noradrenergic agents could have serotonergic effects via a mechanism that is yet to be fully elucidated. The clinical manifestations of SS can be diverse, ranging from mild to severe and potentially fatal symptoms. When administering a combination of catecholaminergic agents, clinicians should carefully monitor the patient's neurologic status for unexpected adverse reactions.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isPartOfCLINICAL NEUROPHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdrenergic Uptake Inhibitors/administration & dosage-
dc.subject.MESHAdrenergic Uptake Inhibitors/adverse effects*-
dc.subject.MESHAkinetic Mutism/diagnostic imaging*-
dc.subject.MESHAkinetic Mutism/drug therapy-
dc.subject.MESHAkinetic Mutism/etiology-
dc.subject.MESHAtomoxetine Hydrochloride/administration & dosage-
dc.subject.MESHAtomoxetine Hydrochloride/adverse effects-
dc.subject.MESHBenserazide/administration & dosage-
dc.subject.MESHBenserazide/adverse effects-
dc.subject.MESHCerebral Hemorrhage/complications-
dc.subject.MESHCerebral Hemorrhage/diagnostic imaging*-
dc.subject.MESHCerebral Hemorrhage/drug therapy-
dc.subject.MESHDopamine Agents/administration & dosage-
dc.subject.MESHDopamine Agents/adverse effects-
dc.subject.MESHDopamine Uptake Inhibitors/administration & dosage-
dc.subject.MESHDopamine Uptake Inhibitors/adverse effects*-
dc.subject.MESHDrug Combinations-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHHumans-
dc.subject.MESHLevodopa/administration & dosage-
dc.subject.MESHLevodopa/adverse effects-
dc.subject.MESHMale-
dc.subject.MESHMethylphenidate/administration & dosage-
dc.subject.MESHMethylphenidate/adverse effects-
dc.subject.MESHMiddle Aged Serotonin Syndrome/chemically induced-
dc.subject.MESHSerotonin Syndrome/complications-
dc.subject.MESHSerotonin Syndrome/diagnostic imaging*-
dc.titleSerotonin Syndrome Following Combined Administration of Dopaminergic and Noradrenergic Agents in a Patient With Akinetic Mutism After Frontal Intracerebral Hemorrhage: A Case Report-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Rehabilitation Medicine-
dc.contributor.googleauthorJeon, Dae Geun-
dc.contributor.googleauthorKim, Yong Wook-
dc.contributor.googleauthorKim, Na Young-
dc.contributor.googleauthorPark, Jung Hyun-
dc.identifier.doi10.1097/WNF.0000000000000220-
dc.contributor.localIdA00350-
dc.contributor.localIdA00750-
dc.contributor.localIdA01682-
dc.contributor.localIdA05404-
dc.relation.journalcodeJ00591-
dc.identifier.eissn1537-162X-
dc.identifier.pmid28622210-
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00002826-201707000-00007&LSLINK=80&D=ovft-
dc.contributor.alternativeNameKim, Na Young-
dc.contributor.alternativeNameKim, Yong Wook-
dc.contributor.alternativeNamePark, Jung Hyun-
dc.contributor.alternativeNameJeon, Dae Geun-
dc.contributor.affiliatedAuthorKim, Na Young-
dc.contributor.affiliatedAuthorKim, Yong Wook-
dc.contributor.affiliatedAuthorPark, Jung Hyun-
dc.contributor.affiliatedAuthorJeon, Dae Geun-
dc.citation.volume40-
dc.citation.number4-
dc.citation.startPage180-
dc.citation.endPage182-
dc.identifier.bibliographicCitationCLINICAL NEUROPHARMACOLOGY, Vol.40(4) : 180-182, 2017-
dc.identifier.rimsid43760-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Rehabilitation Medicine (재활의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.